Tag: headquarters
-
Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint
Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously…
-
Samsung Bioepis seeks Europe approval for its Humira copy
Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira. Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar…
-
Sanofi and Regeneron report positive skin disease trial
French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals. “These are the first long-term Phase 3 data that demonstrated dupilumab with topical corticosteroids was superior to topical corticosteroids alone, and provided sustained…
-
Sanofi and Regeneron report positive skin disease trial
French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals. “These are the first long-term Phase 3 data that demonstrated dupilumab with topical corticosteroids was superior to topical corticosteroids alone, and provided sustained…
-
Study finds targeted cancer drugs may work in range of tumor types
By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the…
-
Study finds targeted cancer drugs may work in range of tumor types
By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the…
-
Bayer CEO expects Monsanto to respond positively to deal proposal
FRANKFURT (Reuters) – German drugs and pesticides group Bayer said it was confident that Monsanto would take a positive view of its $62 billion takeover proposal.
-
Bayer announces $62 billion cash offer for Monsanto
German drugs and chemicals group Bayer AG said it had made an offer to buy U.S. seeds company Monsanto Co for $122 per share in cash, or a total value of $62 billion including debt, to create the world's biggest agricultural supplier. Bayer said on Monday that the proposal made to Monsanto's management represented a…
-
Roche breast cancer drug Perjeta rejected by NICE
Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could…
-
Sanofi ready to up offer for drugmaker Medivation, could oust board
PARIS/NEW YORK (Reuters) – France's Sanofi said it could raise its proposed $9.3 billion deal to buy Medivation if the U.S. cancer drugmaker engaged in talks, threatening to go directly to shareholders to oust the board if not. Sanofi Chief Executive Olivier Brandicourt wrote in a letter to the board of Medivation published on Thursday…